Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

David Clynes, a postdoc in the MRC Molecular Haematology Unit, has been awarded a Children with Cancer UK Research Fellowship.

 This Fellowship scheme aims to support outstanding scientists seeking to develop a career in childhood cancer research and aims to identify ‘research leaders of the future’ providing them with the support they need to achieve their full potential. The Fellowship includes funding for a defined five year programme of work.


David’s research interest centres around a subset of cancers that adopt a specific telomere lengthening mechanism known as the Alternative Lengthening of Telomeres (ALT) pathway, which is thought to involve Homologous recombination (HR) mediated copying of telomeric templates. An important prediction is that ALT positive cancers are susceptible to specific therapeutic treatments. This is particularly important because a variety of clinically difficult to treat pediatric cancers, including currently untreatable brain tumours, such as Glioblastoma Multiforme and Diffuse Intrinsic Pontine Gliomas elongate their telomeres via the ALT pathway. David’s research will explore the molecular mechanisms underlying the ALT pathway with a view to identifying novel druggable targets and small molecule drugs for the rational design of more effective cancer therapies.

Similar stories

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Seven research groups secure LEAF Sustainability Awards

The Laboratory Efficiency Assessment Framework (LEAF) aims to support research groups to embed sustainability into their work.

Blood tests may predict response to immunotherapy for melanoma

A study from the Fairfax lab provides new insight into the factors that determine patient response to Immune Checkpoint Blockers, a common immunotherapy treatment for melanoma.

New Fellowship of the Association of Cancer Physicians

Many congratulations to Prof Adrian Harris (Department of Oncology), who has become a Fellow of the Association of Cancer Physicians.

New “molecular fibres” may help cells repair DNA

Research by the Blackford group has for the first time observed molecular fibres that may hold together sections of broken DNA in mitosis.

MRC WIMM researchers talk about their research on rare diseases

To mark rare disease day we asked our researchers to tell us more about the rare conditions that they study, and why their research is important.